Hormones and hemodynamics in heart failure.

Heart failure is a major cause of cardiovascular mortality and morbidity, resulting in more than 1 million hospitalizations per year, and is the most common hospital-discharge diagnosis among patients older than 65 years.1 In recent years, much has been learned about the pathophysiology of heart failure, particularly in the area of fluid and electrolyte metabolism, and this will be the focus of the present review. Regulation of Body-Fluid Volume There is considerable evidence in support of a unifying hypothesis of the regulation of body-fluid volume that is applicable to patients with edematous disorders such as cardiac failure, to patients with . . .

[1]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[2]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[3]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[4]  W. Abraham,et al.  Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. , 1998, Journal of cardiac failure.

[5]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[6]  R. Schrier,et al.  Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. , 1997, The Journal of clinical investigation.

[7]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[8]  Y. Sugishita,et al.  Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.

[9]  A. Luchner,et al.  Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. , 1996, Kidney international.

[10]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[11]  G. Maurer,et al.  Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. , 1996, Journal of the American College of Cardiology.

[12]  W. Abraham,et al.  Reversal of atrial natriuretic peptide resistance by increasing distal tubular sodium delivery in patients with decompensated cirrhosis , 1995, Hepatology.

[13]  S. Nielsen,et al.  Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Saruta,et al.  Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. , 1994, The American journal of physiology.

[15]  P. Boekstegers,et al.  REPEATED ADMINISTRATION OF A F(ab′)2 FRAGMENT OF AN ANTI‐TUMOR NECROSIS FACTOR α MONOCLONAL ANTIBODY IN PATIENTS WITH SEVERE SEPSIS: EFFECTS ON THE CARDIOVASCULAR SYSTEM AND CYTOKINE LEVELS , 1994, Shock.

[16]  S. Moncada,et al.  The L-arginine-nitric oxide pathway. , 1993, The New England journal of medicine.

[17]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[18]  C. Barberis,et al.  Cloning of the Human Type‐2 Vasopressin Receptor Gene , 1993, Annals of the New York Academy of Sciences.

[19]  R. Ardaillou,et al.  Glomerular effects of angiotensin II: a reappraisal based on studies with non-peptide receptor antagonists. , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[20]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[21]  Schrier Rw A unifying hypothesis of body fluid volume regulation. The Lilly Lecture 1992. , 1992 .

[22]  K Rakusan,et al.  Morphometry of Human Coronary Capillaries During Normal Growth and the Effect of Age in Left Ventricular Pressure‐Overload Hypertrophy , 1992, Circulation.

[23]  B. Groves,et al.  Atrial natriuretic peptide and urinary cyclic guanosine monophosphate in patients with chronic heart failure. , 1992, Journal of the American Society of Nephrology : JASN.

[24]  B. Parsons,et al.  Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.

[25]  K. Pennert,et al.  Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. , 1992, American journal of hypertension.

[26]  R. Schrier,et al.  Pathogenesis of ascites formation : mechanism of impaired aldosterone escape in cirrhosis , 1991 .

[27]  W. Abraham,et al.  Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. , 1991, American journal of nephrology.

[28]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[29]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[30]  R. Schrier Body fluid volume regulation in health and disease: a unifying hypothesis. , 1990, Annals of internal medicine.

[31]  H. Drexler,et al.  Vasodilatory action of endogenous atrial natriuretic factor in a rat model of chronic heart failure as determined by monoclonal ANF antibody. , 1990, Circulation research.

[32]  L. Navar,et al.  Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. , 1989, The American journal of physiology.

[33]  W. Suki Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure. , 1989, Archives of internal medicine.

[34]  R. Schrier,et al.  Enzymatic and binding effects of atrial natriuretic factor in glomeruli and nephrons. , 1989, Kidney international.

[35]  W. Oelkers,et al.  Effects of Incremental Infusions of Atrial Natriuretic Factor on Aldosterone, Renin, and Blood Pressure in Humans , 1988, Hypertension.

[36]  G. Dibona,et al.  Neural control of renal function in edema-forming states. , 1988, The American journal of physiology.

[37]  R. Schrier Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2) , 1988, The New England journal of medicine.

[38]  H. Itoh,et al.  Atrial natriuretic polypeptide (ANP) in human ventricle. Increased gene expression of ANP in dilated cardiomyopathy. , 1987, Biochemical and biophysical research communications.

[39]  Andrew,et al.  Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. , 1986, The Journal of clinical investigation.

[40]  B. Brenner,et al.  Renal and Systemic Hemodynamic Effects of Synthetic Atrial Natriuretic Peptide in the Anesthetized Rat , 1986, Circulation research.

[41]  K. Okada,et al.  Effect of vasopressin antagonist on water excretion in inferior vena cava constriction. , 1986, Kidney international.

[42]  M. Packer,et al.  Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. , 1986, Circulation.

[43]  C. Johnston,et al.  Role of Vasopressin in Experimental Congestive Cardiac Failure , 1986, Journal of cardiovascular pharmacology.

[44]  B. Rolls,et al.  Angiotensin II-induced thirst and vasopressin release in man. , 1985, Clinical science.

[45]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[46]  J. Cohn,et al.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.

[47]  S. Satoh,et al.  Effects of renal nerve stimulation, norepinephrine and angiotensin II on renal blood flow in relation to release of PG-like substances in anesthetized dogs. , 1981, Archives internationales de pharmacodynamie et de therapie.

[48]  T. Berl,et al.  Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. , 1981, The New England journal of medicine.

[49]  R. Venuto,et al.  Acute oliguric renal failure induced by indomethacin: possible mechanism. , 1979, Annals of internal medicine.

[50]  T. Berl,et al.  Osmotic and nonosmotic control of vasopressin release. , 1979, The American journal of physiology.

[51]  C. W. Gottschalk,et al.  Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. , 1976, The Journal of clinical investigation.

[52]  B. Brenner,et al.  Effects of Norepinephrine and Angiotensin II on the Determinants of Glomerular Ultrafiltration and Proximal Tubule Fluid Reabsorption in the Rat , 1975, Circulation research.

[53]  T. Berl,et al.  Mechanism of effect of alpha adrenergic stimulation with norepinephrine on renal water excretion. , 1973, The Journal of clinical investigation.

[54]  J. P. Gilmore,et al.  Contribution of Baroreceptors to the Control of Renal Function , 1964, Circulation research.

[55]  J. Henry,et al.  The effect of negative pressure breathing on urine flow. , 1954, The Journal of clinical investigation.